136 related articles for article (PubMed ID: 15723219)
1. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Kishida O; Miyazaki Y; Murayama Y; Ogasa M; Miyazaki T; Yamamoto T; Watabe K; Tsutsui S; Kiyohara T; Shimomura I; Shinomura Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):584-94. PubMed ID: 15723219
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Kishida O; Miyazaki Y; Murayama Y; Ogasa M; Miyazaki T; Yamamoto T; Watabe K; Tsutsui S; Kiyohara T; Shimomura I; Shinomura Y
Cancer Chemother Pharmacol; 2005 Apr; 55(4):393-403. PubMed ID: 15723263
[TBL] [Abstract][Full Text] [Related]
3. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
[TBL] [Abstract][Full Text] [Related]
4. Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
Rodrigues S; Attoub S; Nguyen QD; Bruyneel E; Rodrigue CM; Westley BR; May FE; Thim L; Mareel M; Emami S; Gespach C
Oncogene; 2003 Jul; 22(29):4488-97. PubMed ID: 12881705
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
8. Autocrine ligands for the epidermal growth factor receptor mediate interleukin-8 release from bronchial epithelial cells in response to cigarette smoke.
Richter A; O'Donnell RA; Powell RM; Sanders MW; Holgate ST; Djukanović R; Davies DE
Am J Respir Cell Mol Biol; 2002 Jul; 27(1):85-90. PubMed ID: 12091250
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone signaling in preovulatory follicles involves early activation of the epidermal growth factor receptor pathway.
Panigone S; Hsieh M; Fu M; Persani L; Conti M
Mol Endocrinol; 2008 Apr; 22(4):924-36. PubMed ID: 18187604
[TBL] [Abstract][Full Text] [Related]
10. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
11. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
[TBL] [Abstract][Full Text] [Related]
13. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Azzariti A; Xu JM; Porcelli L; Paradiso A
Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
[TBL] [Abstract][Full Text] [Related]
14. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Wakeling AE; Guy SP; Woodburn JR; Ashton SE; Curry BJ; Barker AJ; Gibson KH
Cancer Res; 2002 Oct; 62(20):5749-54. PubMed ID: 12384534
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
[TBL] [Abstract][Full Text] [Related]
17. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
19. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor.
Ogunwobi OO; Beales IL
Br J Biomed Sci; 2008; 65(3):121-7. PubMed ID: 18986098
[TBL] [Abstract][Full Text] [Related]
20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
